|
2-Methyl-1,5,7,8-tetrahydro-thiopyrano [4,3-d]pyrimidin-4-one |
PARP inhibitior XI |
AL-RS-00001 |
|
6-((7-((1-aminocyclopropyl)methoxy)- 6-methoxyquinolin-4-yl)oxy)-N-methyl-1-naphthamide dihydrochloride |
Dual VEGFR/FGFR tyrosine kinase inhibitor |
AL-RS-00002 |
|
(R)-6-[4-[(4-ethyl-1-piperazinyl)methyl]phenyl]- N-(1-phenylethyl)-7H-Pyrrolo[2,3-d]pyrimidin-4-amine |
EGFR/ErbB2 and VEGFR kinase inhibitor |
AL-RS-00003 |
|
(E)-3-(pyridin-3-yl)-1-(pyridin-4-yl)prop-2-en-1-one |
PFKFB3 Inhibitior |
AL-RS-00004 |
|
8-Formyl-7-hydroxy-4-methyl-2H-1benzopyran-2-one |
IRE1 alpha inhibitor |
AL-RS-00005 |
|
5-(4-ethylbenzylidene)-2-thioxothiazolidin-4-one |
c-Myc inhibitor |
AL-RS-00006 |
|
4-(3-(6-methylpyridin-2-yl)-1H-pyrazol-4-yl) quinoline |
ALK5 inhibitor |
AL-RS-00007 |
|
(E)-2-Cyano-3-(3,4 dihydrophenyl)-N(phenylmethyl)- 2-propenamide |
JAK2 inhibitior -AG-490 |
AL-RS-00009 |
|
7-methoxy-4-((6-phenyl-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)methylphenyl- [1,2,4]triazolo[4,3-b]pyridazin-3-yl)methoxy)quinoline |
c-MET receptor tyrosine kinase (RTK)- AMG 208 |
AL-RS-00010 |
|
N-(4-(3-(2-aminopyrimidin-4-yl)pyridin-2-yloxy)phenyl)-4 -(4-methylthiophen-2-yl)phthalazin-1-amine |
pan-aurora kinases Inhibitor- AMG 900 |
AL-RS-00011 |
|
1-cyclopropyl-3-(3-(6-(morpholinomethyl)-1H-benzo[d]imidazol-2-yl)- 1H-pyrazol-4-yl)urea |
Dual Aurora/JAK inhibitor - AT 9283 |
AL-RS-00012 |
|
(5S,8S,10aR)-N-benzhydryl-5-((S)-2-(methylamino)propanamido)-3- (3-methylbutanoyl)-6-oxodecahydropyrrolo[1,2-a][1,5]diazocine-8-carboxamide |
IAP(Inhibitor of apoptosis proteins) antagonist- AT 406 |
AL-RS-00013 |
|
3-(Cyano-dimethyl-methyl)-N-[4-methyl-3-(3-methyl-4-oxo-3,4-dihydro-quinazolin-6-ylamino)- phenyl]-benzamide |
C-Raf inhibitor |
AL-RS-00014 |
|
N-(4-(4-aminopiperidin-1-yl)-2-methoxyphenyl) -5-chloro-4-(1H-indol-3-yl)pyrimidin-2-amine |
ALK/IGF1R inhibitor AZD 3463 |
AL-RS-00015 |
|
5-(3-Fluoro-phenyl)-3-ureido-thiophene-2-carboxylic acid (S)- piperidin-3-ylamide hydrochloride |
CHK inhibitor |
AL-RS-00016 |
|
2-(5-(4-bromobenzylidene)-4-oxo-2-thioxothiazolidin-3-yl)- 3-methylbutanoic acid |
Bcl-xL antagonist BH3I-1 |
AL-RS-00017 |
|
N-[4-[(3-Chloro-4-fluorophenyl)amino]-7-[[(3''S'')-tetrahydro-3- furanyl]oxy]-6-quinazolinyl]-4(dimethylamino)-2-butenamide |
EGFR/HER2 inhibitor BIBW 2992- Afatinib |
AL-RS-00018 |
|
1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3 -[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-urea |
p38 MAPK inhibitor BIRB 796 - Doramapimod |
AL-RS-00019 |
|
Pyrrolidine-1-carboxylic acid (3-{5-bromo-4- [2-(1H-imidazol-4-yl)-ethylamino]-pyrimidin-2-ylamino}-phenyl)-amide |
PDK1 inhibitor - BX 912 |
AL-RS-00020 |
|
N3-(4-fluorophenyl)-1H-pyrazolo[3,4-d]pyrimidine- 3,4-diamine |
MNK1 inhibitor - CGP 57380 |
AL-RS-00021 |
|
5-(3-chlorophenylamino) benzo[c][2,6]naphthyridine- 8-carboxylic acid hydrochloride |
CK2 inhibitor - CX 4945 hydrochloride Silmitasertib hydrochloride |
AL-RS-00022 |
|
4-(acetylamino)-N-(2-amino-phenyl) benzamide |
HDAC inhibitor- CI 994 PD 123654 - Tacedinaline |
AL-RS-00023 |
|
Pyridin-3-ylmethyl N-[[4-[(2-aminophenyl) carbamoyl]phenyl]methyl]carbamate |
HDAC inhibitor- MS 275 - Entinostat SNDX 275 |
AL-RS-00024 |
|
N-Hydroxy-1-(4-methoxybenzyl)-1H-indole-6- carboxamide |
HDAC8 inhibitor- PCI 34051 |
AL-RS-00025 |
|
N-[2-[3-(piperazin-1-ylmethyl)imidazo[2,1-b][1,3]thiazol- 6-yl]phenyl]quinoxaline-2-carboxamide tetrahydrochloride |
SIRT1 activator- SRT 1720 tetrahydrochloride |
AL-RS-00026 |
|
6-Chloro-2,3,4,9-tetrahydro-1H-carbazole-1- carboxamide |
Sirt1 inhibitor- Selisistat - EX 527 |
AL-RS-00027 |
|
4-[4-[[5-(4,5-Dimethyl-2-nitrophenyl)-2- furanyl]methylene]-4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-1-yl]benzoic acid |
p300 HAT inhibitor- C 646 |
AL-RS-00028 |
|
7-​[3-​(dimethylamino)propoxy]-​2-​(hexahydro-​4-​ methyl-​1H-​1,​4-​diazepin-​1-​yl)- ​6-​methoxy-​N-​(1-​methyl-​4-​ piperidinyl)-​4-​quinazolinamine |
HMTase inhibitor- UNC 0224 |
AL-RS-00028 |
|
2-Cyclohexyl-N-(1-isopropylpiperidin-4-yl)-6-methoxy-7- (3-(pyrrolidin-1-yl)propoxy) quinazolin-4-amine |
G9a/GLP inhibitor- UNC 0638 |
AL-RS-00029 |
|
N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5- (ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(morpholinomethyl)biphenyl-3-carboxamide |
EZH2 inhibitor- EPZ 6438 |
AL-RS-00030 |
|
4-amino-N-phenethyl benzenesulfonamide |
PRMT1 inhibitor- C-7280948 |
AL-RS-00031 |
|
4'-((trans)-2-aminocyclopropyl)biphenyl-3-ol hydrochloride |
LSD1 inhibitor- OG-L002 |
AL-RS-00032 |
|
2-Methoxy-N-(3-methyl-2-oxo-1,2,3,4-tetrahydro-quinazolin-6-yl) -bezenesulfonamide |
BET inhibitor- PFI-1 |
AL-RS-00033 |
|
2-(4-(2-hydroxyethoxy)-3,5-dimethylphenyl)-5,7- dimethoxyquinazolin-4(3H)-one |
BET BD2 inhibitor- RVX 208 |
AL-RS-00034 |
|
(S)-2-cyano-1-(1-phenylethyl)-3-(quinolin-5-yl) guanidine |
P2X7 antagonist - A 804598 |
AL-RS-00035 |
|
1-(7-Methoxyquinolin-4-yl)-3-[6-(trifluoromethyl) pyridin-2-yl]urea |
GSK3 inhibitor- A 1070722 |
AL-RS-00036 |
|
4-(benzylamino)-2-(3-chloro-4-hydroxyphenethylamino) pyrimidine-5-carboxamide |
STAT6 inhibitor- AS 1517499 |
AL-RS-00037 |
|
(S)-1-(2-hydroxy-1-phenylethyl)-3-(4-(pyridin-4-yl) phenyl)urea |
ROCK inhibitor- AS 1892802 |
AL-RS-00038 |
|
4-(3-(2H-1,2,3-triazol-2-yl)phenylamino)-2-((1R,2S)- 2-aminocyclohexylamino) pyrimidine-5-carboxamide |
Syk inhibitor-P505-15 |
AL-RS-00039 |
|
2-(4-ethoxyphenyl)-3-(4-methylsulfonylphenyl) pyrazolo[1,5-b]pyridazine |
COX-2 inhibitor- GW 406381 |
AL-RS-00040 |
|
N-3-Pyridinyl-4-[[3-[[5-(trifluoromethyl)- 2-pyridinyl]oxy]phenyl]methyl]-1-piperidine carboxamide |
FAAH inhibitor-PF 3845 |
AL-RS-00041 |
|
8-(5-chloro-2-(4-methylpiperazin-1-yl)isonicotinamido)- 1-(4-fluorophenyl)-4,5-dihydro-1H-benzo[g]indazole-3-carboxamide |
IKK-2 inhibitor-PHA 408 |
AL-RS-00042 |
|
1H-Pyrrole-2,5-dione, 1-[6-[[(17b)-3-methoxyestra-1,3,5 (10)-trien-17-yl]amino]hexyl]- |
Phospholipase C inhibitor- U 73122 |
AL-RS-00043 |
|
5-Bromo-N-(4,5-dihydro-1H-imidazol-2-yl) quinoxalin-6-amine (2R,3R)-2,3-dihydroxybutanedioate |
alpha-2 agonist - Brimonidine |
AL-RS-00044 |
|
2-(3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)- 1-(ethylsulfonyl)azetidin-3-yl)acetonitrile |
JAK1/JAK2 inhibitor- Baricitinib INCB 028050 - LY 3009104 |
AL-RS-00045 |
|
4-(2-(3-chlorobenzamido)-4-(2,4-dichlorophenethylcarbamoyl)phenyl)- N-ethyl-1,4-diazepane-1-carboxamide |
CXCR3 antagonist |
AL-RS-00046 |
|
(1R,2R)-2-(4'-(3-phenylureido)biphenylcarbonyl) cyclopentanecarboxylic acid |
DGAT-1 inhibitor - A 922500 |
AL-RS-00047 |
|
N-(2-fluoro-4-methanesulfonylphenyl)-(6-[4-(3-isopropyl-[1,2,4]oxadiazol-5-yl)-piperidin-1-yl]-5-nitro-pyrimidin-4-yl)amine |
GPR119 agonist- AR 231453 |
AL-RS-00048 |
|
(3R,5R)-7-(2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-(phenylcarbamoyl) -1H-pyrrol-1-yl)-3,5-dihydroxyheptanoate hemicalcium salt |
HMG-CoA inhibitor- Atorvastatin calcium |
AL-RS-00049 |
|
N-[4,5-Dimethyl-1-(2-methyl-benzyl)-1H- imidazol-2-ylmethyl]-2,4-dimethoxy-N-(3-methyl-butyl)-benzamide |
GLP-1 antagonist |
AL-RS-00050 |
|
3-chloro-2-methyl-N-(4-(2-(4-methylpiperazin-1-yl)- 2-oxoethyl)thiazol-2-yl)benzenesulfonamide hydrochloride |
11beta-HSD1 inhibitor - BVT 2733 |
AL-RS-00051 |
|
3-[3-Acetyl-4-(3-tert-butylamino-2-hydroxy-propoxy)- phenyl]-1,1-diethyl-urea hydrochloride |
Beta 1 blocker – Celiprolol |
AL-RS-00052 |
|
(S)-2-(3-(1-(2-(4-isopropylphenyl)acetyl)piperidin-3-yl)phenoxy)- 2-methylpropanoic acid |
PPARα agonist- CP 775146 |
AL-RS-00053 |
|
4-(((6-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)-2- (trifluoromethyl)pyridin-3-yl)(methyl)amino)methyl)benzoic acid |
FXR agonist - PX 20350 |
AL-RS-00054 |
|
S-[2-({[1-(2-ethylbutyl)cyclohexyl]carbonyl}amino) phenyl] 2-methylpropanethioate |
CETP inhibitor- Dalcetrapib - JTT 705 |
AL-RS-00055 |
|
4-Chloro-N-[2-[[5-(trifluoromethyl)-2-pyridinyl]sulfonyl] ethyl]benzamide |
PPAR δ antgonist- GSK 3787 |
AL-RS-00056 |
|
(2R,3S,4S,5R,6S)-2-(hydroxymethyl)-6-(4-(4-isopropoxybenzyl)-1 -isopropyl-5-methyl-1H-pyrazol-3-yloxy)tetrahydro-2H-pyran-3,4,5-triol |
SGLT2 inhibitor- Remogliflozin GSK 189074 |
AL-RS-00057 |
|
3-(4-(3-phenoxybenzylamino)phenyl)propanoic acid |
GPR40 agonist- GW 9508 |
AL-RS-00058 |
|
3-(4-((4-fluoro-4'-methylbiphenyl-2-yl)methoxy)phenyl) propanoic acid |
GPR120/FFA4 agonist- TUG 891 |
AL-RS-00059 |
|
(-)-(2S)-1-(((3-hydroxytricyclo(3.3.1.1(3,7))dec-1-yl) amino)acetyl)pyrrolidine-2-carbonitrile |
DPP4 inhibitor- Vildagliptin - NVP- LAF237 |
AL-RS-00060 |
|
2R,3R,4R,5S)-1-(2-hydroxyethyl)-2-(hydroxymethyl)piperidine -3,4,5-triol |
alpha-Glucosidase inhibitor - Miglitol |
AL-RS-00061 |
|
3-(1H-tetrazol-5-yl)-1,4,5,6-tetrahydro- cyclopentapyrazol |
Niacin receptor partial agonist- MK 0354 |
AL-RS-00062 |
|
3-Cyclopentyl-2-(4-methanesulfonyl-phenyl)-N- thiazol-2-yl-propionamide |
Glucokinase activator- RO 28-0450 |
AL-RS-00063 |
